University of Montana ScholarWorks at University of Montana

Syllabi

Course Syllabi

Fall 9-1-2000

PHAR 595.01: Therapeutics III

Michael P. Rivey University of Montana - Missoula, michael.rivey@umontana.edu

Douglas Allington University of Montana - Missoula, douglas.allington@umontana.edu

Donna G. Beall University of Montana - Missoula, donna.beall@umontana.edu

Follow this and additional works at: https://scholarworks.umt.edu/syllabi Let us know how access to this document benefits you.

Recommended Citation

Rivey, Michael P.; Allington, Douglas; and Beall, Donna G., "PHAR 595.01: Therapeutics III" (2000). *Syllabi*. 5280.

https://scholarworks.umt.edu/syllabi/5280

This Syllabus is brought to you for free and open access by the Course Syllabi at ScholarWorks at University of Montana. It has been accepted for inclusion in Syllabi by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact scholarworks@mso.umt.edu.

 Pharma 	cy 552 & 595 B.S. : Therapeutics III (+) Fall 2000
(note: Fri-M	0910-1000 Rm 111, Skaggs Building Ion joint lectures with Pharm.D class in SB114) lectures on Thurs 1010-1100 in SB 336)
Course Coordinator:	
Instructors:	Douglas AllingtonOffice: 243-6796Rose MacklinCommunity Hosp: 728-4100Cathy Bartelsext. 7605Sarah MillerPager: 329-6122Gayle CochranHome: 251-3369Donna BeallLarry Dent
and a state of the second second	Lee Ann Bradley Vince Colucci addition and additional and additional additionadditional additionadditionadditionadditionad additionadditionad a
Material and Resources	and to invite an besed level when as to represent gene entrated if
Required Texts:	DiPiro Pharmacotherapy, 4 th edition Pray Nonprescription Product Therapeutics or APhA: Handbook of Nonprescription Drugs Medical Letter on Drugs & Therapeutics
	Goodman & Gilman's <i>Pharmacological Basis of Therapeutics</i> Boh <i>Clinical Clerkship Manual</i> A medical dictionary
Optional Texts: Ye	Murphy: Clinical Pharmacokinetics pocket reference Evans: Applied Pharmacokinetics Young, Koda-Kimble: Applied Therapeutics Herfindal, Gourley, Hart: Clinical Pharmacy and Therapeutics Hansten & Horn: Drug Interactions Pagana & Pagana: Diagnostic & Lab Test Ref., or other lab. text

Goals of the Course

To promote the students' understanding of common disease states with particular emphasis on the facets of diseases that are amenable to drug therapy.

To familiarize the student with the proper use of drugs in a clinical setting.

To develop the students' awareness of factors that should be considered prior to selection of a drug and the appropriate parameters that should be monitored for therapeutic as well as undesired effects.

To encourage the students' ability to problem-solve in the clinical setting.

GRADING IN COURSE: Phar 552-BS Therapeutics

3 midterm exams: 100 points each Final exam (comprehensive, multiple choice) (100 pts comprehensive, 30 pts over last 6 lectures) 300 points 130 points

Topic quizzes: 8 quizzes graded on 10 pts each

Bonus pts > 75%

TOTAL POINTS FOR COURSE

430 POINTS

Class quizzes: The purposes of the quizzes are to promote reading of the text before a topic and encourage class attendance and attention. Quizzes will occur after topic lectures and will test understanding of basic concepts in the reading assignments as well as issues discussed or emphasized in lecture. A quiz will consist of 5 multiple choice or true/false questions, each worth 2 points. **Quiz** on syllabus indicates a quiz will be given for the overall topic at end of the given lecture. Lowest 2 quiz grades will be thrown out; no make-ups will be allowed for quiz. **Scoring:** Quiz performance can only benefit student; bonus points for the course will be awarded for all points over 75% (i.e. 60 pts) of the potential total 80 pts on the quizzes (10 total quizzes – 2 throw-outs = 8x10 pts)

NOTE: Reading assignments are from DiPiro (4th edition) & Pray books

Integrated Studies Conferences: you will be assigned to a conference based on period you registered for; instructors are not necessarily the ones under which you registered. Attendance/make-up is required for all topics/cases; you may attend a different conference in order to complete the assignment, with instructor permission. The "make-up" requirement for a conference will be at the discretion of the instructor, dependent on the topic.

Exams:

3 midterm exams: Tests will be in "traditional" case report fashion with short answers required. Tests will be given during a "common" time period of 8-10AM on select Thursdays. B.S. and Pharm.D. classes will take tests simultaneously.

Final exam: 65 multiple choice questions worth 2 pts each. Effort will be made to design questions in the style similar to the NAPLEX exam.

Class civility: Your **student colleagues** have strongly indicated to us that they wish to spend their valuable time in class listening to therapeutics topics. They **do not** appreciate any "side" conversations while the instructor is lecturing. They **do** appreciate students raising questions about important lecture aspects for further discussion or clarification.

Out of respect for your classmates, we will not tolerate excessive and disruptive talking during lecture. The instructor may first ask you to be silent; you may be asked to leave class if you persist in disruptive talking. The instructor will be the judge of "what" constitutes disruption. Please note that we **encourage** questions and relevant discussion.

Performance Objectives provide a second state of the test of t

Upon completion of this course, each student shall be able to:

Relate the pathophysiology of a disease to the known or purported action of a drug.

Evaluate the seriousness of a disorder based on the signs and symptoms related to a diagnosed problem, and:

--determine the necessity of drug therapy,

--when applicable, choose the proper drug and/or

drug product for the situation.

PROVINCIAL BOOMS REPORT

Determine the place of non-pharmacologic and natural therapies, when applicable.

Tailor the drug therapy of an individual based on patient characteristics and known pharmacokinetics principles. Identify potential drug-drug interactions.

Monitor the appropriate parameters of a disease to determine if the patient is responding positively to the apy.

Monitor for adverse drug reactions and exacerbations of underlying patient problems resulting from drug therapy.

Student Responsibilities and Obligations

(40)동 18일 - 영화 (19일 - 1998년 1월 19일 - 1 - 19일 - 1 - 19일 - 193 - 1

* To attend and participate in lecture sessions.

* To do assigned readings from the texts.

The set of the seco

2

* To attend Integrated Studies conferences, prepare each case in advance, prepare to present a patient case, and participate in the discussion of all patient presentations.

* To perform satisfactorily on course quizzes and lecture examinations.

GRADING IN COURSE: Phar 552-BS Therapeutics

3 midterm exams: 100 points each Final exam (comprehensive, multiple choice) (100 pts comprehensive, 30 pts over last 6 lectures)

Topic quizzes: 8 quizzes graded on 10 pts each

300 points 130 points

430 POINTS

Bonus pts > 75%

TOTAL POINTS FOR COURSE

Class quizzes: The purposes of the quizzes are to promote reading of the text before a topic and encourage class attendance and attention. Quizzes will occur after topic lectures and will test understanding of basic concepts in the reading assignments as well as issues discussed or emphasized in lecture. A quiz will consist of 5 multiple choice or true/false questions, each worth 2 points. **Quiz** on syllabus indicates a quiz will be given for the overall topic at end of the given lecture. Lowest 2 quiz grades will be thrown out; **no make-ups will be allowed** for quiz. **Scoring:** Quiz performance can only benefit student; bonus points for the course will be awarded for all points over 75% (i.e. 60 pts) of the potential total 80 pts on the quizzes (10 total quizzes – 2 throw-outs = 8x10 pts)

NOTE: Reading assignments are from DiPiro (4th edition) & Pray books

Integrated Studies Conferences: you will be assigned to a conference based on period you registered for; instructors are not necessarily the ones under which you registered. Attendance/make-up is required for all topics/cases; you may attend a different conference in order to complete the assignment, with instructor permission. The "make-up" requirement for a conference will be at the discretion of the instructor, dependent on the topic.

Exams:

3 midterm exams: Tests will be in "traditional" case report fashion with short answers required. Tests will be given during a "common" time period of 8-10AM on select Thursdays. B.S. and Pharm.D. classes will take tests simultaneously.

Final exam: 65 multiple choice questions worth 2 pts each. Effort will be made to design questions in the style similar to the NAPLEX exam.

Class civility: Your **student colleagues** have strongly indicated to us that they wish to spend their valuable time in class listening to therapeutics topics. They **do not** appreciate any "side" conversations while the instructor is lecturing. They **do** appreciate students raising questions about important lecture aspects for further discussion or clarification.

Out of respect for your classmates, we will not tolerate excessive and disruptive talking during lecture. The instructor may first ask you to be silent; you may be asked to leave class if you persist in disruptive talking. The instructor will be the judge of "what" constitutes disruption. Please note that we **encourage** questions and relevant discussion.

Therapeutics III 552 B.S. & Phar 595 supplemental course: Lecture Syllabus

		andag 200		Reading (DiPiro, Pray)
Sept	t 6W	Introduction/ Liver disease	MPR	n swie winnen n
	7Th	Liver disease	MPR	35, 38
	7Th	Liver disease (10AM in SB 114)	MPR (595)	
	8F 🖉	Renal disease (10AM in SB 114)	DRA	40 messae 8 - secondar 1
	11M	Renal disease/ quiz	DRA	:42 000 (1995) 17 A (995) A (695)
		Hypertension	LAD	JNC-6
	14Th	HTN 2 Still to grabe a storma to at the s	LAD	10
	14Th	HTNETE UDDO livy served of others	LAD (595)	· 「「「」」 「「」」 「」」 「」」 「」」 「」」 「」」 「」」 」 「」」 「」」 」 「」」 」 「」」 」 「」」 」 」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」 「」」」
	15F	Pain Management (10 AM SB114)	LAB	56, OTC 18
		will consist of 5 multiple choice or type		si ni besiak iqirin ili hokeyosib -
		Pain mgmt (10AM SB114)/ quiz	LAB	ngog S (move does priotesta)
		Hyperlipidemia and another struct Caranae	LAD	19 cm to provide organitations
		Hyperlipidemia	LAD	
		Drug Literature Evaluation	CLB (595)	z zakóo strati siniad suriori
	22F	Headache (10AM SB 114)	DB States	57
	25M	Headache (10AM SB 114)	DB	OTC 18
	27W	Congestive Heart Failure	VJC	11
	28Th	CHF/ quiz (10-11AM)	VJC	an ata ". Anima A an an an
	28Th	Drug Literature Evaluation (9-10AM)	CLB (595)	an a contra contra contra a seconda a seconda de seconda de seconda de seconda de seconda de seconda de second Alterna de seconda de se
	29F	Digoxin kinetics	VJC	
		°qu-skant" ant" noisiin veq vitouusmi	differ , means	HERE HE MARMON OF SHARING
Oct		Dig. PK-b. total means and to ourse your	VJC	AUCTIN GERLEN PARAMENTER
	4W	OFF DAY; CAREER FAIR		
	5 Th	Test 1 at 8-10AM in SB 114; through	-	
	5Th		CLB (595)	
	6F		VJC ·	12 wat show making a
		name no MACT 3 to burned and throng	ioo i a pravoa	The set the start has seen
	9M	CAD view and the set of i	VJC	L mare bus 2.8 averant
	11W	Dysrhythmias	VJC	14
	12Th	Arthritis flow world lates and interm	MPR	83,84
	12Th	Arthritis 2004 a pr	MPR (595)	Warten Hill
	13F	Arthritis/ quiz	MPR	() I C 18.20
	1.6.1.4		nd saupekity PP	
	1 011			
	181	contraception/ quiz		An and the second s
	1910	Diabetes mellitis		🛠 e sesteres graat
	191h	Contraception/ quiz	ND (090)	Entre a constraint of the
	20F	DIVISION CONTRACTOR CONTRACTOR CONTRACTOR CONTRACTOR		
			· 建筑作用,作品。**	and a second day " search and a fi
		经济 建橡胶蛋白 形成 医二乙烯醇 网络拉马勒拉马马勒拉马马马勒勒马马	In Teach Annas a	a second a second se

4

552-Ther III & Phar 595, continued

g 1

.

*				· · · · · · · · · · · · · · · · · · · ·
Oct	23M	DM/ quiz	LRM	OTC 46
		Menopause	GAC	78
		Menopause	GAC	n o k ana ang katalan Ang sa Alah Kana Berkara Nyada
		Drug Literature Evaluation	CLB (595)	
	27F	💳 la la companya di seconda	GAC	82, OTC pp.711,713
	30M	•	GAC	
Nov	1W	Dementia	GAC	61. 1941 and 38-SEC 1955
	2Th	Test 2 at 8-10AM in SB 114; through	-	
	2Th		CLB (595)	
	3F	Fluid & electrolytes	SJM	DiPiro pp, 890-901
		MI DOMERATION EVENT DOLLARDING IN	SJM	or pp. 902-16
	6M 8W	Fluid & electrolytes Nutrition	SJM	pp. 902-10
	9Th		CLB	DiPiro pp.2013-41
	9Th		CLB (595)	
	10F	VETERANS DAY HOLIDAY	·	
	13M	Oncology	CLB	
	15W	Nausea & vomiting	LAB	33, OTC 5
	16Th	Seizure disorders	DRA	52
	16Th	• • • •	DRA (595)	
	17F	Anticonvulsant kinetics	DRA	
	2014	Thromboembolic dx (10AM in SB114)		
		OFF TOALEL DAN		17
	22VV	THANKSGIVING HOLIDAY	198 yenau //	n on i diaman (in the second
	24F	THANKSGIVING HOLIDAY		
		The share of the second second	a. V. a	
	27M	TED (10AM in SB 114)/ quiz	MPR	vois or beginning suberin?
			MPR	18
	30Th	Thyroid disorders	MPR	7119-11 - 20062 - 20010-00001 24-066 - 0160
	30Th	Biostatistics overview	TPS (595)	
Dec	1F	Obstructive Airways Disease (10AM in		
				24, OTC 17
				25. And the graph of the
			DRA	· · · · · · · · · · · · · · · · · · ·
7Th test 3 at 8-10AM in SB 114; through OAD				
		그는 그는 것 같아요. 아이는 것 같아요. 이렇게 방법을 가지 않았다. 것은 가지만 것이 같아요. 이렇게 가지 않는 것이 같아요. 이렇게 많아요.	TPS (595)	
	8F	Anxiety/sleep disorders	MJD	67,69, OTC 24

5

552-Ther III & Phar 595, continued	6- 6-
 11M Attention deficit disorder 13W CLASS EVALUATION/ gout 14Th Depression 14Th Biostatistics overview 15F Depression/ quiz 	WJD DiPiro pp. 1046-49 MPR 85 WJD 65 TPS (595) WJD
Phar 552-BS Final: test 4, 130 pts comprehe	nsive multiple choice NAPLEX/PSAP format
· · · · · · · · · · · · · · · · · · ·	onarten un a la consta ten en la della
	The Drug Location By Institute
NOTE: class will meet at 10AM on certain Mo	
	PAL Fead or a correction PAL for a correction
	en e
	TE Drug Literature Examples
$\mathcal{L} = \mathcal{L} = $	
88 N K	
	· 如此是一个人的问题。
Pharmany 595, supplemental source	CLATERIA POR CONTRACTOR
Pharmacy 595: supplemental course	ee m MACT) to ploche state (
Phar 595: Course is 1-hour Thursday session not in B.S. curriculum in an overview fashion.	二十二日 「「「「「「」」」「「「「「「」」」」「「「」」」」「「「」」」」」「「」」」」
Schedule: merged to above syllabus (weekly	y on Thurs at 1010-1100 in SB 336)
Instructors: various Therapeutics instructors	普通的有限 一分行行
Cathy Bartels	1993 Mary Mary Mary
lim Stratton	shin finethe dies overview - D Overnor e Anwe s Geeen Hill
	an in the sport of the second s
Grading in Phar 595:	
	anders anderson (NA) NAS ELL State Madifus a Constant
3/14 of course grade:biostatistics question5/14 of course grade:grade obtained in The	ns on Final Exam (add-on questions) er. Phar 552 course

Integrated Studies Phar 574

Conference topics

١.

Group 1: Group 2:	SB 337 SB 215	Tues 0910-1100 Colucci """ Rivey
week of:		
September	4M	no conference
	11M	Liver disease case
	18M	Hypertension case
	25M	Headache/pain management
October	2M	Digoxin kinetics
	9M	service learning update: J-club for ½ of class
	16M	OTC cases
	23M	Contraception
	30M	Diabetes
November	6M	service learning update: J-club for other ½ of class
	13M	SEMINARS
	20M	off week- holiday week
	27M	TED case
December	4M	OAD case
	11M	OTC cases

Seminar: A required activity in the course, graded on a pass/no-pass basis. Student must repeat a no-pass seminar to successfully pass course.